Preview

FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology

Advanced search

The use of various genetically engineered biological drugs and selective immunosuppressants within the current provider-payment model of russian diagnosis-related groups

https://doi.org/10.17749/2070-4909/farmakoekonomika.2020.058

Full Text:

Abstract

Diagnosis-Related Groups (DRG) for the payment for biological therapy were created at the stage of the pilot project and their coefficients of input intensity were not revised since then. The expansion of the range of genetically-engineered biological drugs (GEBD) and the development of new indications for biological therapy and new groups of expensive drugs (like selective immunodepressants, SI) determine the necessity in the differentiated payment for the therapy with GEBD and SI. However, at the federal level, this will be possible only after the approval of the clinical recommendations.

Aim. The study aimed to identify possible applications of different GEBD and SI within the current provider-payment model of the Russian diagnosis-related group in terms of bronchial asthma (BA) and inflammatory bowel disease (IBD) - Crohn's disease and ulcerative colitis.

Materials and methods. The expenses on GEBD and SI for one case of hospitalization were calculated and compared with the imposed tariffs. For the evaluation of the possibility of the provision of an expensive treatment within the existing DRG model, the authors modeled the distribution of patients with BA and IBD by different pharmaceutical treatment plans in the current practice and cases of an increase in the share of indications of more expensive therapy. The authors identified the number of patients that could have been treated without an increase in the costs of compulsory medical insurance (CHI). The authors proposed the subgroups for the differentiated payment for the treatment of BA and IBD with GEBD and SI.

Results. Few variants of treatment with GEBD and SI were characterized by the costs of drugs that would exceed an average payment rate for DRG st36.003 and ds36.004 in 2020. In the model, an increase in the share of patients that received the most expensive drugs of all the registered GEBD and SI in the RF for the treatment of BA and IBD did not lead to an increase in the costs for CHI. It is possible to maintain the initial volume of the financing and increase the number of patients that receive GEBD and SI due to a decrease in the number of hospitalizations. The authors identified approximate values of the coefficient of input intensity (CII) for the subgroups that can be formed for the differentiated payment for pharmaceutical treatment with GEBD and SI.

Conclusion. Despite the fact that without the recalculation of CII, there were numerous changed introduced into DRGs st36.003 and ds36.004 “Treatment with GEBD and SI” and the spectrum of the associated clinical situations expanded, it was possible to maintain the possibility of the payment for the therapy with different drugs, including the most expensive ones without an increase in the costs for the CHI system. Still, the results of the present study indicate the necessity in the optimization of the system of payment for medical care with genetically-engineered biologic drugs and selective immunodepressants through the implementation of a differentiated approach to the payment at the federal level.

About the Authors

E. V. Derkach
Russian Presidential Academy of National Economy and Public Administration; National Center for Health Technology Assessment
Russian Federation

Elena V. Derkach – MD, PhD, Leading Researcher, Laboratory for Health Technology Assessment, Institute for Applied Economic Research; director, 82 Vernadskogo prospect, Moscow 119571, Russia; 12 Butlerova Str., Moscow 117485, Russia



E. A. Pyadushkina
Russian Presidential Academy of National Economy and Public Administration; National Center for Health Technology Assessment
Russian Federation

Elena A. Pyadushkina – Researcher, Laboratory for Assessment of Technologies in Healthcare, Institute of Applied Economic Research; Deputy Head of the Department of Clinical and Economic Analysis, Researcher ID: P-8218-2014, 82 Vernadskogo prospect, Moscow 119571, Russia; 12 Butlerova Str., Moscow 117485, Russia



M. V. Avxentyeva
Russian Presidential Academy of National Economy and Public Administration; Sechenov University
Russian Federation

Maria V. Avxentyeva – MD, Dr Sci Med, Leading Researcher, Laboratory for Health Technology Assessment, Institute for Applied Economic Research; Professor, High School of Healthcare Administration, Scopus Author ID: 56308310000, 82 Vernadskogo prospect, Moscow 119571, Russia; 8-2 Trubetskaya Str., Moscow 119048, Russia



T. V. Boyarskaya
National Center for Health Technology Assessment
Russian Federation
Tatiana V. Boyarskaya – Researcher, Department of Evidence-Based Medicine, Biostatistics and Mathematical Modeling, 12 Butlerova Str., Moscow 117485, Russia


E. E. Yagnenkova
National Center for Health Technology Assessment
Russian Federation
Ekaterina E. Yagnenkova – Junior Researcher, Department of Clinical and Economic Analysis, Biostatistics and Mathematical Modeling, 12 Butlerova Str., Moscow 117485, Russia


A. S. Mokrova
National Center for Health Technology Assessment
Russian Federation
Anna S. Mokrova – Junior Researcher, Department of Clinical and Economic Analysis, 12 Butlerova Str., Moscow 117485, Russia


M. M. Maryanyan
National Center for Health Technology Assessment
Russian Federation

Monika M. Maryanyan – Junior Researcher, Department of Clinical and Economic Analysis, Scopus Author ID: 57207733583, 12 Butlerova Str., Moscow 117485, Russia



References

1. Avksentyeva M. V., Salakhutdinova S. K. Diagnosis-related groups as a new method of payment for inpatient and day care in the Russian Federation. Lekarstvennyi vestnik. 2016; 10 (2–62): 31–36 (in Russ).

2. Sura M. V. Diagnosis-Related Groups in the System of Compulsory Health Insurance. Possibilities of Payment for Medical Care of Patients, who Need Administration of Genetically Engineered Biological Drugs. Meditsinskie tekhnologii. Otsenka i vybor. 2016; 1 (23): 24–34 (in Russ).

3. Avksentyeva M.V., Omelyanovskiy V.V., Petrovskiy A.V., Davydov M.I., Zheleznyakova I.A., Tyulyandin S.A., Ledovskikh Yu.A., Tryakin A.A., Zuev A.V., Fedyaev D.V., Fedyanin M.Yu., Gordeev S.S., Lazareva M.L., Semakova E.V., Kravtsov A.A. New Approaches to the Development of Diagnostic Related Groups for Antineoplastic Pharmacotherapy in Russian Federation. Meditsinskie tekhnologii. Otsenka i vybor. 2018; 2 (32): 8–22 (in Russ).

4. State Register of Medicines. [Electronic resource] URL: https://grls.rosminzdrav.ru/grls.aspx. Accessed: 10.04.2020. (in Russ).

5. Order of the Government of the Russian Federation of 12.10.2019 N 2406-r "On approval of the list of vital and essential drugs for 2020, as well as lists of drugs for medical use and the minimum range of drugs necessary for the provision of medical care" [Electronic resource] URL: https://urlid.ru/c882. Accessed: 10.04.2020. (in Russ).

6. State register of maximum selling prices of the manufacturer [Electronic resource] URL: https://grls.rosminzdrav.ru/pricelims.aspx. Accessed: 10.04.2020. (in Russ).

7. The official website of the unified information system in the field of procurement [Electronic resource] URL: https://zakupki.gov.ru/epz/main/public/home.html. Accessed: 10.04.2020. (in Russ).

8. FFOMS order of November 21, 2018 No. 247 "On the establishment of requirements for the structure and content of the tariff agreement" (Registered with the Ministry of Justice of the Russian Federation on December 25, 2018 N 53153) [Electronic resource] URL: https://minjust.consultant.ru/documents/41404. Accessed:10.04.2020. (in Russ).

9. Decree of the Government of the Russian Federation No. 1610 of December 17, 2019 "On the Program of State Guarantees of Free Provision of Medical Care to Citizens for 2020 and for the Planning Period of 2021 and 2022" (in Russ).

10. Nedogoda S.V., Salasyuk A.S., Barykina I.N., Smirnova V.O., Frolov M.Yu. Сost of the Biological Therapy for Severe Bronchcial Asthma at Inpatient and Day Care Setting Meditsinskie tekhnologii. Otsenka i vybor. 2020; (1): 61–69. https://doi.org/10.31556/2219-0678.2020.39.1.061-069. (in Russ).


For citation:


Derkach E.V., Pyadushkina E.A., Avxentyeva M.V., Boyarskaya T.V., Yagnenkova E.E., Mokrova A.S., Maryanyan M.M. The use of various genetically engineered biological drugs and selective immunosuppressants within the current provider-payment model of russian diagnosis-related groups. FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology. 2020;13(3):225-239. (In Russ.) https://doi.org/10.17749/2070-4909/farmakoekonomika.2020.058

Views: 364


ISSN 2070-4909 (Print)
ISSN 2070-4933 (Online)